ARIAD PHARM INC, (ARIA) Stock Research Free Stock Rating

Company Profile

ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines to treat cancer by regulating cell signaling with small molecules. It primarily focuses on a series of product candidates for oncology indications, including AP23573 to treat solid tumors and hematologic malignancies; AP23464 to treat certain forms of leukemia and to block the spread of cancer, a cause of morbidity and mortality in cancer; and bone-targeted mammalian target of rapamycin inhibitor program, based on AP23841 to treat cancer that has spread to bone and to treat primary bone cancers, such as osteogenic sarcomas. AP23573 can also be used in drug-delivery stents to reduce reblockage of arteries following angioplasty and stenting. The company also develops a proprietary portfolio of cell-signaling regulation technologies to control intracellular processes with small molecules, providing tools for application in cell biology, functional genomics, proteomics, and drug discovery research, as well as in regulated protein and cell therapy. In addition, the company has an exclusive license to technology and patents related to the discovery, development, and use of drugs to regulate NF-kB cell-signaling activity, which can be used in treating disorders that include inflammation, sepsis, cancer, and osteoporosis. ARIAD was founded in 1991 by Harvey J. Berger and is headquartered in Cambridge, Massachusetts.

Latest Headlines

ARIAD to Present at the Piper Jaffray 20th Annual Healthcare Conference (Business Wire)

ARIAD to Present Preclinical Data on Multi-Targeted Kinase Inhibitor at 50th Ash Annual Meeting (Business Wire)

Navigating the Micro-Cap Biotech Minefield (at Seeking Alpha)

ARIAD PHARMACEUTICALS INC Financials (EDGAR Online Financials)

ARIAD To Present at the Lazard Capital Markets 5th Annual Healthcare Conference (Business Wire)

ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (EDGAR Online)

New Star Analyst Rankings for ARIAD PHARM INC (StarMine)

ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure (EDGAR Online)

ARAID Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript (at Seeking Alpha)

ARIAD Pharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today (CCBN)